| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() FDA Approves Velosulin BR For Diabetes Treatment PRINCETON, NJ -- July 20, 1999 -- The United States Food and Drug Administration has approved Novo Nordisk A/S’ Velosulin(R)BR (human buffered regular insulin [rDNA origin] injection) for people with diabetes. It is indicated for use in external insulin infusion pumps and with U-100 insulin syringes. Novo Nordisk will begin marketing recombinant Velosulin BR later this year and it will eventually replace the semi-synthetic version of Velosulin BR that is currently available. The active drug in the recombinant form of Velosulin BR is structurally identical to the insulin produced by the pancreas in the human body. The formulation is not significantly different from semi- synthetic Velosulin BR, which has been available for pump use in the U.S. since 1986. In the U.S., approximately five percent of people with type I diabetes use an insulin pump to help manage their diabetes.
|